Sign in
Taking people in SpainPhase 2

K1-70 for Active Thyroid Eye Disease in People With Graves' Disease

Tests K1-70 against placebo for bulging eyes in active thyroid eye disease.

Key facts

Who runs it
Av7 Limited
Where
Barcelona, Cordoba, Granada, Madrid, and Sevilla, SpainSee the 5 sitesAlso in 1 other country, 3 sites
Registry title
Study to Assess K1-70 in Participants with Active Thyroid Eye Disease
Status
Recruiting
Phase
Phase 2
People taking part
50 people, planned
Started
28 May 2026
Expected to end
27 May 2028
Type of study
Interventional
Record updated
16 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Graves' disease and active thyroid eye disease with bulging eyes. It compares K1-70 with placebo (a dummy treatment).

Age
18 to 75 years
Sex
Men and women
Disease stage
Active thyroid eye disease, moderate to severe (eyelid pulling back, soft-tissue changes or double vision). Shown by MRI swelling of eye muscles, or a Clinical activity score (CAS) of at least 3. Eye bulging of ≥18 mm, or at least 3 mm more than the other eye. Symptoms within the 12 months before screening. Thyroid function normal or only mildly high or low.
Earlier treatment
No eye-socket radiotherapy or surgery for thyroid eye disease. No corticosteroids by mouth, vein, eye-socket injection or eye drops within 3 weeks before consent. No rituximab within 12 months, tocilizumab within 6 months, other immune-suppressing drugs within 3 months, or botulinum toxin around the eyes within 3 months.

Main reasons for not taking part

  • Damage to the optic nerve from thyroid eye disease, or very severe eye disease with risk of blindness
  • CAS dropped by 2 or more points, or eye bulging dropped by 2 mm or more, between screening and baseline
  • Past eye-socket radiotherapy or surgery for thyroid eye disease
  • Recent corticosteroid, rituximab, tocilizumab, immune-suppressing drug or botulinum toxin treatment
  • Other eye disease that the doctor thinks would stop participation

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Subjects must satisfy all the following criteria to be enrolled in the study 1. Is a male or female subject aged 18 to 75 years of age inclusive, at the time of signing and dating the informed consent form (ICF)
  • Must sign and date the ICF indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
  • Have clinically confirmed Graves’ disease with active thyroid eye disease at screening and baseline, with the study eye satisfying criterion a) or b). Criterion a) will be used if magnetic resonance imaging (MRI) is available and criterion b) will be used if not. a) Have inflammatory hypertrophy of the extraocular muscles as shown by MRI according to the criteria of the 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. b) The Clinical activity score (CAS) is at least 3
  • Has exophthalmos of ≥18 mm in the study eye, or if <18mm in the study eye there is at least 3 mm greater proptosis in the study eye compared to the fellow eye
  • Have any symptoms of eyelid retraction, soft-tissue findings, or diplopia as defined in the criteria for moderate to severe eye disease in the 2021 EUGOGO clinical practice guidelines for the medical management of Graves' orbitopathy
  • Has self-reported symptoms of active thyroid eye disease within the 12 months prior to Screening
  • Has Graves' disease whose underlying condition is controlled and has normal thyroid function at the time of screening or has mild hypothyroidism or hyperthyroidism.Every effort should be made to maintain thyroid function throughout the study”
  • Is a female of childbearing potential or male with a female partner of childbearing potential who consents to use acceptable contraceptive methods as defined in the protocol. Additional inclusion criteria are outlined in the study protocol

Who cannot take part

  • Has received a systemic corticosteroid (IV or orally), intraorbital corticosteroid injection, or ophthalmic corticosteroid drug for treating thyroid eye disease or another medical condition within the 3 weeks prior to providing informed consent. None of these corticosteroid treatments may be started during the study period. This excludes corticosteroids that are locally administered to an area not near the orbits (e.g., topical corticosteroids, intraarticular corticosteroid injections, and inhaled corticosteroids) and corticosteroids for treating infusion-related reactions
  • Has had any previous systemic treatment with rituximab (Rituxan®) within the 12 months prior to the start of study drug administration, tocilizumab (Actemra®) within the 6 months prior to the start of study drug administration, or any systemic non-steroid immunosuppressive agent within the 3 months prior to the start of study drug administration
  • Have received treatment around the eyes with botulinum toxin within the 3 months prior to the start of study drug administration; 8.Has a pre-existing ophthalmic disease that, in the opinion of the investigator, would preclude study participation or complicate interpretation of the study results Additional exclusion criteria are outlined in the study protocol
  • Individuals who meet any of the following criteria will be excluded from the study : 1. Has dysthyroid optic neuropathy and/or very severe eye disease (with the risk of blindness) that features ulceration, perforation or necrosis of the cornea and requires urgent therapeutic intervention
  • Has a history of orbital radiotherapy or surgery for thyroid eye disease
  • Whose CAS decreased by 2 or more points in the study eye from screening to baseline
  • Whose exophthalmos decreased by 2 mm or more in the study eye from screening to baseline

Where in Spain

Also in 1 other country, 3 sites

  • Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
  • Clinica De Oftalmologia De Cordoba S.L.Cordoba, SpainTaking people
  • Hospital Universitario Virgen de las NievesGranada, SpainTaking people
  • Hospital Universitario Ramón y CajalMadrid, SpainTaking people
  • Hospital Universitario Virgen De La MacarenaSevilla, SpainTaking people

About the trial

What the trial wants to find out

To compare the exophthalmos improvement rate achieved with K1-70 once every 6 weeks (q6W) for 24 weeks with that achieved with placebo in subjects with Graves’ disease and active thyroid eye disease.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2, Randomised, Double-masked, Placebo-controlled, Parallel-group, Multi-centre Study to Evaluate K1-70 in Patients with Active Thyroid Eye Disease in Europe
Plain-language title
K1-70 for Active Thyroid Eye Disease in People With Graves' DiseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
16 February 2026